This CME activity will review recent advances in the diagnosis, treatment and management of patients with non-alcoholic steatohepatitis (NASH) as presented at Digestive Disease Week (DDW) 2019 in San Diego, California. The three expert faculty will review the pathophysiology of NASH as well as discuss the latest emerging therapeutic options for the treatment of the disease. The faculty will also examine strategies for utilizing an interprofessional team approach to patient care to improve outcomes for in the non-alcoholic steatohepatitis landscape. Upon completion of this discussion-based activity, learners will gain insight into current treatment and management techniques for non-alcoholic steatohepatitis patients.
Gastroenterologists, hepatologists, endocrinologists, diabetologists, and other healthcare providers involved in the management of NASH
1.Review the pathogenesis of non-alcoholic steatohepatitis for informed clinical decision making
2. Analyze the latest clinical trial data for emerging therapeutic options for the treatment of non-alcoholic steatohepatitis, including data presented at DDW 2019
3. Collaborate with the healthcare team to optimize outcomes for patients with non-alcoholic steatohepatitis
Zobair M. Younossi, MD, MPH, FAASLD
Chairman, Department of Medicine
Inova Fairfax Hospital
Vice President for Research, Inova Health System
Professor of Medicine
Virginia Commonwealth University, Inova Campus
Falls Church, VA
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Zobair Younossi, MD, MPH||Consultant/Advisor: Bristol-Myers Squibb Company; Echosens; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis; Novo Nordisk; Siemens Healthineers AG; Terns Pharmaceuticals; Viking TherapeuticsGrant/Research Support: Bristol-Myers Squibb Company; Echosens; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis; Novo Nordisk; Siemens Healthineers AG; Terns Pharmaceuticals; Viking Therapeutics|
|Kenneth Cusi, MD||Consultant/Advisor: Allergan plc; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Poxel Pharmaceuticals; Pfizer Inc.Grant/Research Support: Cirius Therapeutics; Eli Lilly and Company; Pharma; Janssen Pharmaceutica; Novartis International AG; Novo Nordisk, Zydus Pharmaceuticals|
|Ira M. Jacobson, MD||Consultant/Advisor: Assembly Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceutica; Merck & Co., Inc.; Novo Nordisk; Siemens Healthineers AG; Spring Bank Pharmaceuticals IncGrant/Research Support: Assembly Pharmaceuticals, Inc.; Enanta, Genfit, Gilead Sciences Inc.; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceutica; Merck & Co., Inc.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Intercept Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Intercept Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].